相关临床试验
78
8 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1785
进行中（未招募）
2
2.6%
已完成
54
69.2%
Enrolling By Invitation
1
1.3%
尚未招募
5
6.4%
招募中
10
12.8%
Unknown
5
6.4%
撤回
1
1.3%
暂无批准数据
- A University of Georgia study analyzing U.S. Census Bureau and Bureau of Labor Statistics data covering more than 20 million workers found medical cannabis legalization is associated with a 6.9% reduction in health-related workplace absences. - The sharpest declines occurred in physically demanding roles, with manual laborers missing work 39% less and industrial machine operators 33% less, while recreational cannabis laws showed no statistically significant effect. - Corresponding author Patryk Babiarz estimated medical marijuana could save hundreds of millions of dollars annually, citing an estimate of $225 billion in annual lost productivity from employee absenteeism. - The study relied on self-reported survey data and did not measure individual cannabis use, duration of sick leave, or potential negative health outcomes, limiting causal interpretation.
- Bioxytran has initiated a research collaboration with the University of Georgia to evaluate its lead drug candidate PHM23 against the H5N1 bird flu virus as part of a $100 million grant program. - The company's novel galectin antagonist PHM23 targets viral replication by blocking spike proteins from attaching to host cells, with in vitro studies already demonstrating effectiveness against H5N1-similar viruses. - UGA selected PHM23 for inclusion in its USDA grant submission to the $100 million HPAI Poultry Innovation Grand Challenge, highlighting the scientific promise of this approach. - The collaboration aims to develop a humane alternative to current outbreak management protocols that require mass culling of entire flocks, potentially saving billions in economic losses.
- Cornell researchers have bioengineered bacteria with a unique enzyme from Desulfovibrio marinus to attach glycans to monoclonal antibodies, potentially democratizing access to therapeutic antibody drugs. - The breakthrough addresses a key limitation of bacterial production systems by enabling protein glycosylation, which impacts over 50% of human proteins and is critical for antibody immune function. - The engineered E. coli bacteria could offer dramatically accelerated production speeds and significantly lower costs compared to conventional Chinese hamster ovary cell manufacturing methods. - The technology could enable production of antibody drugs for cancer, autoimmune, and infectious diseases, though optimization for higher production titers remains necessary.
- Peach Bowl, Inc. donated $2.5 million to the Aflac Cancer and Blood Disorders Center, expanding support for 18 promising pediatric cancer clinical trials across seven facilities nationwide. - The donation builds on the original $20 million Peach Bowl LegACy Fund established in 2019, with 79 children currently enrolled in various cancer drug trials. - Four new trials launched in the latest funding cycle include studies of tumor-suppressing drugs, immunotherapy for osteosarcoma, brain tumor treatments, and prevention of transplant complications. - The fund was created in honor of Anna Charles Hollis, who died from acute myeloid leukemia in 2018, and aims to accelerate novel cancer treatments from bench to bedside.
- AN2 Therapeutics and DNDi announced a collaboration to advance clinical development of AN2-502998, an oral drug candidate with curative potential for chronic Chagas disease affecting 6-7 million people worldwide. - The boron-based benzoxaborole compound targets CPSF3 in T. cruzi parasites, utilizing the same mechanism as acoziborole which achieved ~95% cure rates in African sleeping sickness trials. - Phase 1 first-in-human studies are underway with completion expected in the second half of 2025, followed by Phase 2 proof-of-concept trials planned for 2026. - DNDi will provide extensive clinical trial networks across Latin America and Spain, leveraging their established Chagas Clinical Research Platform to accelerate global access to this potential breakthrough therapy.
- Blue Lake Biotechnology and CyanVac published full Phase 1 data in Science Advances showing their intranasal COVID-19 vaccine candidate CVXGA demonstrated safety and immunogenicity in 72 healthy subjects aged 12-51 years. - The single-dose PIV5-vectored vaccine achieved 92% CD8+ T cell response rates in low-dose groups and 89% in high-dose groups, with 31-41% of high-dose participants developing three-fold increases in mucosal antibodies. - High-dose CVXGA1 showed 67.8% relative vaccine effectiveness against symptomatic COVID-19 infection at 7.3 months post-vaccination compared to low-dose recipients (p=0.048). - The vaccine stimulated all three pillars of immunity—humoral, cellular, and mucosal—with minimal reactogenicity and no serious adverse events related to vaccination.
- Bioxytran's antiviral compound PHM23 has been selected by the University of Georgia for inclusion in their grant submission to the USDA's $100 million Highly Pathogenic Avian Influenza Poultry Innovation Grand Challenge. - The galectin antagonist technology behind PHM23 works by blocking viral spike proteins from attaching to host cells, demonstrating effectiveness against viruses similar to Bird Flu (H5N1) in laboratory studies. - This recognition highlights PHM23's potential as a broad-spectrum antiviral that could help contain H5N1 outbreaks, potentially eliminating the need for mass culling and reducing billions in annual losses to the poultry industry.
- Updated 2024 RSV vaccination guidelines now strongly recommend vaccination for adults 75 and older, while those 60-74 with risk factors should receive the shot, replacing previous shared decision-making approach. - Pharmacists are positioned as key advocates for RSV vaccination, responsible for patient education, identifying eligible individuals, and ensuring proper vaccine administration in the community setting. - A new mRNA-based RSV vaccine joins the market as the third FDA-approved option, featuring a ready-to-use formulation that streamlines the vaccination process for healthcare providers.
- Blue Lake Biotechnology's experimental nasal COVID-19 vaccine demonstrated 86% efficacy in reducing symptomatic infections for three months in Phase 1 trials, significantly outperforming existing mRNA boosters. - The vaccine uses a modified parainfluenza virus platform to deliver coronavirus spike protein directly to the nasal cavity, creating targeted immune protection at the virus entry point. - Phase 1 results from 72 participants showed superior tolerability with minimal side effects compared to traditional injected vaccines, with the company planning to expand to 400 participants in upcoming Phase 2 trials. - The nasal delivery approach represents a promising next-generation vaccine strategy that could provide more durable and effective protection against respiratory viruses.
